Literature DB >> 9032317

Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function.

R A McDonald1, D L Mayers, R C Chung, K F Wagner, S Ratto-Kim, D L Birx, N L Michael.   

Abstract

We examined the relationship between env sequence variation and disease progression in 10 human immunodeficiency virus type 1 (HIV-1)-seropositive subjects selected from a longitudinal cohort receiving zidovudine therapy. Five subjects were chosen for stable clinical status and CD4 counts (slow progressors), and five were selected for rapid clinical deterioration and CD4 count decline (rapid progressors). The slow progressors had significantly lower plasma viral RNA loads and greater lymphoproliferative responses to mitogens than the rapid progressors. DNA sequences representing the C1 through C3 regions of env were amplified from two peripheral blood mononuclear cell DNA samples from each subject separated by an average of 2.5 years. Molecular clones of these amplicons were then sequenced, and DNA sequence and deduced amino acid sequence distances were compared. Inter-time point sequence comparison showed a higher rate of sequence evolution for the rapid progressors in three of five matched pairs of rapid progressors and slow progressors and for the slow progressors in the remaining two subject pairs. However, intra-time point sequence comparisons showed that four of five slow progressors developed a more diverse quasispecies over time and one showed no change. In contrast, four of five rapid progressors showed no change in quasispecies diversity over time and one showed a significant decrease in diversity. The overall C1 through C3 region quasispecies diversity in the slow progressors at baseline was lower than that for the rapid progressors, but this difference was not significant at the follow-up time points. These diversity relationships were obscured if sequence analyses were limited to the 300-bp C2 to V3 region. Thus, HIV-1 quasispecies diversity increased over time in subjects with more functional immune systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032317      PMCID: PMC191257     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development.

Authors:  J Goudsmit; N K Back; P L Nara
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.

Authors:  A Meyerhans; R Cheynier; J Albert; M Seth; S Kwok; J Sninsky; L Morfeldt-Månson; B Asjö; S Wain-Hobson
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions.

Authors:  M Goodenow; T Huet; W Saurin; S Kwok; J Sninsky; S Wain-Hobson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

6.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.

Authors:  M Nei; T Gojobori
Journal:  Mol Biol Evol       Date:  1986-09       Impact factor: 16.240

7.  The initial immune response to HIV and immune system activation determine the outcome of HIV disease.

Authors:  H W Sheppard; M S Ascher; B McRae; R E Anderson; W Lang; J P Allain
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

8.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

9.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.

Authors:  B H Hahn; G M Shaw; M E Taylor; R R Redfield; P D Markham; S Z Salahuddin; F Wong-Staal; R C Gallo; E S Parks; W P Parks
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

10.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

View more
  21 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Genetic drift and within-host metapopulation dynamics of HIV-1 infection.

Authors:  S D Frost; M J Dumaurier; S Wain-Hobson; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

3.  Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals.

Authors:  Alan R Templeton; Rebecca A Reichert; Anton E Weisstein; Xiao-Fang Yu; Richard B Markham
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

4.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Authors:  R B Markham; W C Wang; A E Weisstein; Z Wang; A Munoz; A Templeton; J Margolick; D Vlahov; T Quinn; H Farzadegan; X F Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  The explosive human immunodeficiency virus type 1 epidemic among injecting drug users of Kathmandu, Nepal, is caused by a subtype C virus of restricted genetic diversity.

Authors:  R B Oelrichs; I L Shrestha; D A Anderson; N J Deacon
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  High rate of recombination throughout the human immunodeficiency virus type 1 genome.

Authors:  A E Jetzt; H Yu; G J Klarmann; Y Ron; B D Preston; J P Dougherty
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection.

Authors:  A B van 't Wout; H Blaak; L J Ran; M Brouwer; C Kuiken; H Schuitemaker
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.

Authors:  Manish Sagar; Erin Kirkegaard; E Michelle Long; Connie Celum; Susan Buchbinder; Eric S Daar; Julie Overbaugh
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.

Authors:  Sally L Painter; Roman Biek; David C Holley; Mary Poss
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.